AR065070A1 - Sal de estronico de atorvastatina y una composicion farmaceutica que la comprende - Google Patents

Sal de estronico de atorvastatina y una composicion farmaceutica que la comprende

Info

Publication number
AR065070A1
AR065070A1 ARP080100349A ARP080100349A AR065070A1 AR 065070 A1 AR065070 A1 AR 065070A1 AR P080100349 A ARP080100349 A AR P080100349A AR P080100349 A ARP080100349 A AR P080100349A AR 065070 A1 AR065070 A1 AR 065070A1
Authority
AR
Argentina
Prior art keywords
atorvastatin
salt
pharmaceutical composition
estronic
hydrates
Prior art date
Application number
ARP080100349A
Other languages
English (en)
Inventor
Sun Young Jang
Eun Sook Kim
Bo Sung Kwon
Sangmin Yun
Kwee Hyun Suh
Gwan Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR065070A1 publication Critical patent/AR065070A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Una sal que es util para la prevencion o el tratamiento de hiperlipidemia y hipercolesterolemia, y una composicion farmacéutica que comprende la misma. Reivindicacion 1: La sal de estroncio de atorvastatina, caracterizada por la formula (1), o sus hidratos o polimorfos. Reivindicacion 2: La sal de estroncio de atorvastatina o sus hidratos o polimorfos de acuerdo con la reivindicacion 1, caracterizada porque es una forma cristalina. Reivindicacion 3: La sal de estroncio de atorvastatina o sus hidratos o polimorfos de acuerdo con la reivindicacion 2, caracterizada porque está representada por la formula (2).
ARP080100349A 2007-01-29 2008-01-29 Sal de estronico de atorvastatina y una composicion farmaceutica que la comprende AR065070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070008896A KR100878140B1 (ko) 2007-01-29 2007-01-29 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
AR065070A1 true AR065070A1 (es) 2009-05-13

Family

ID=39674220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100349A AR065070A1 (es) 2007-01-29 2008-01-29 Sal de estronico de atorvastatina y una composicion farmaceutica que la comprende

Country Status (16)

Country Link
US (1) US20100120888A1 (es)
EP (1) EP2121596A4 (es)
JP (1) JP2010516756A (es)
KR (1) KR100878140B1 (es)
CN (1) CN101600688A (es)
AR (1) AR065070A1 (es)
AU (1) AU2008211906B2 (es)
BR (1) BRPI0808369A2 (es)
CA (1) CA2675996A1 (es)
CL (1) CL2008000170A1 (es)
IL (1) IL200069A0 (es)
MX (1) MX2009007922A (es)
NZ (1) NZ579339A (es)
PE (1) PE20081722A1 (es)
TW (1) TW200844093A (es)
WO (1) WO2008093951A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101973922B (zh) * 2009-05-27 2013-01-23 天津和美生物技术有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2013107236A1 (zh) * 2012-01-20 2013-07-25 连云港金康和信药业有限公司 （6s）-5-甲基四氢叶酸盐晶型及其制备方法
CN102935076A (zh) * 2012-11-29 2013-02-20 康普药业股份有限公司 一种含阿托伐他汀钠的胶囊及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE284868T1 (de) * 1995-07-17 2005-01-15 Warner Lambert Co Kristaline (r-(r*,r*))-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1- heptancarbonsäure hemi calcium sslz (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CA2450111C (en) 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
JP4954867B2 (ja) * 2004-05-06 2012-06-20 オステオロジックス エイ／エス 有機金属塩類を製造するための高収率で迅速な合成法
AU2005254155A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain

Also Published As

Publication number Publication date
KR20080070951A (ko) 2008-08-01
EP2121596A1 (en) 2009-11-25
EP2121596A4 (en) 2010-03-17
PE20081722A1 (es) 2009-01-22
AU2008211906A1 (en) 2008-08-07
IL200069A0 (en) 2010-04-15
CN101600688A (zh) 2009-12-09
KR100878140B1 (ko) 2009-01-12
TW200844093A (en) 2008-11-16
WO2008093951A1 (en) 2008-08-07
MX2009007922A (es) 2009-08-07
AU2008211906B2 (en) 2010-11-18
BRPI0808369A2 (pt) 2014-08-19
US20100120888A1 (en) 2010-05-13
JP2010516756A (ja) 2010-05-20
CA2675996A1 (en) 2008-08-07
NZ579339A (en) 2011-03-31
CL2008000170A1 (es) 2008-05-23

Similar Documents

Publication Publication Date Title
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
CU23515A3 (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
CY1114533T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν ροζουβαστατινικο ασβεστιο
CR11470A (es) Compuestos organicos
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
UY31084A1 (es) Compuestos de azaindol para la inhibicion de b-secretasa
CR10479A (es) Modulares bencimidazolicos de vr1
EA201100037A1 (ru) Органические соединения
CL2008000316A1 (es) Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara
HK1168096A1 (en) 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
TN2011000291A1 (en) Purine compounds
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
IN2012DN02502A (es)
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
PE20080175A1 (es) Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
AR065070A1 (es) Sal de estronico de atorvastatina y una composicion farmaceutica que la comprende
BR112012024586A2 (pt) compostos de purina
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
UY31469A1 (es) Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal